Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Key Takeaways CRSP is advancing CTX310 and CTX320 in early trials targeting heart disease-linked genetic factors. CTX310 showed up to 82% TG and 81% LDL reduction in early dose-dependent trial results. CRSP plans to add two more in vivo programs by year-end.CRISPR Therapeutics (CRSP) is currently the only company in the world to have secured approval for a CRISPR-based gene therapy developed in partnership with Vertex Pharmaceuticals. Following the landmark success with Casgevy, an ex vivo therapy, the co ...